Beyond cancer, the beneficial effects of MitoQ on various diseases have been previously documented, including the inhibition of prostatic hyperplasia via androgen receptor and NOD-like receptor family pyrin domain-containing 3 inhibition [68,69,70,71,72,73,74]. This evidence concerns the gene AR and benign prostatic hyperplasia.